Revvity stock has delivered a 27.6% decline over the past five years, yet the Discounted Cash Flow (DCF) intrinsic value estimate points to around 22.7% upside from today’s price while earnings based multiples still look rich, leaving investors with a split valuation message.

• Over five years, Revvity is down 27.6%, which means anyone who bought and held through that period has faced a meaningfully negative total return.
• The recent integration of Revvity’s Signals AI software with Anthropic’s Claude platform can support expectations for recurring software revenue, while the risk is that the market questions how quickly this kind of AI driven R&D tooling turns into durable cash flow.
• On Simply Wall St’s broader checks, Revvity scores 3 out of 6, which is a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether the intrinsic value case or the richer earnings multiples will prove to be the better guide for where Revvity’s valuation settles next.

Is Revvity Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Revvity is expected to generate for shareholders and discounts it back to today.

On this view, Revvity’s latest twelve month free cash flow is about $486.9 million, and analysts plus modelled assumptions point to growing free cash flow rather than shrinking it over time. Feeding those projections into a 2 Stage Free Cash Flow to Equity framework produces an estimated intrinsic value of about $143.85 per share.

With the current share price sitting below that estimate, the DCF output implies roughly 22.7% upside, so Revvity screens as undervalued on a cash flow basis. Because the recent integration of Signals AI with Anthropic’s Claude workbench supports expectations for recurring software driven cash flows, it helps explain why the intrinsic value sits above where the market is pricing the stock today.

On the DCF numbers alone, Revvity looks undervalued relative to the cash flows analysts and the model expect it to produce.

Our Discounted Cash Flow (DCF) analysis suggests Revvity is undervalued by 22.7%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Has Revvity Run Too Far on Earnings?

The P/E ratio is a straightforward way to see what you are paying for each dollar of Revvity earnings. Right now, Revvity trades on about 51.9x earnings, which is higher than the Life Sciences industry average of roughly 38.4x and also above the peer average of about 89.6x that includes some very highly rated stocks.

On Simply Wall St’s fair multiple framework, which looks at factors like growth, margins, size and risk, a P/E of about 25.1x would be more in line with Revvity’s profile. That is a wide gap to the current 51.9x P/E. This suggests investors are paying a premium compared with what this tailored benchmark implies, even after considering Revvity’s push into software and AI driven tools.

On the P/E multiple, Revvity stock screens as overvalued relative to both its own fair ratio and the wider Life Sciences group.

The Revvity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Revvity pick up where this valuation split leaves you. They spell out which assumptions about Revvity's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St's Community page. Each narrative ties a specific fair value to a clear set of potential catalysts and risks, so you can see over time which version of Revvity's story appears to be unfolding.

The Revvity community is split, with one camp leaning into the AI and genomics upside while the other worries about regulation, pricing pressure and execution.

Bull case: 22% undervalued

"Analyst consensus recognizes the growth potential in the Genomics England partnership, but this narrative understates the impact of newborn whole genome sequencing as a springboard for global market adoption..."

Bear case: 24% overvalued

"Accelerating regulatory and reimbursement shifts in China, such as the DRG debundling policy, are causing a sustained, high-teen percentage decline in Revvity's high-margin immunodiagnostics business..."

Do you think there's more to the story for Revvity? Head over to our Community to see what others are saying!

The Bottom Line

Revvity sits in a genuine valuation tug of war, with the Discounted Cash Flow (DCF) intrinsic value suggesting upside while the earnings multiple signals the stock is overvalued. The gap comes from what investors prioritise: cash flow potential over time versus what the market is currently willing to pay for each dollar of earnings. Broader checks sit in the middle, so the key question from here is whether Revvity can turn its AI and software efforts into dependable cash flows strong enough to justify both the intrinsic value case and the premium P/E that the market is currently assigning.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.